Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Trichomegaly following treatment with gefitinib (ZD1839).

Literature DB >> 15541102

Trichomegaly following treatment with gefitinib (ZD1839).

J C Pascual, J Bañuls, I Belinchon, M Blanes, B Massuti.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2004 PMID： 15541102 DOI： 10.1111/j.1365-2133.2004.06265.x

Source DB: PubMed Journal: Br J Dermatol ISSN： 0007-0963 Impact factor: 9.302

Keyword Cloud
Cited

× No keyword cloud information.

11 in total

1. Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review.

Authors: Shan-Bing Wang; Kai-Jian Lei; Jia-Pei Liu; Yu-Ming Jia
Journal: Oncol Lett Date: 2015-05-26 Impact factor: 2.967

2. Gefitinib-induced hair alterations.

Authors: Song Zheng; Yue-Long Pan; Jiao-Li Wang; Ke-Er Huang; Ji-Hong Liu; Jian Wang; Xue-Qing Chen
Journal: BMJ Case Rep Date: 2009-03-17

Review 3. Hair disorders in patients with cancer.

Authors: Azael Freites-Martinez; Jerry Shapiro; Shari Goldfarb; Julie Nangia; Joaquin J Jimenez; Ralf Paus; Mario E Lacouture
Journal: J Am Acad Dermatol Date: 2018-04-14 Impact factor: 11.527

4. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer.

Authors: M Fakih; M Vincent
Journal: Curr Oncol Date: 2010-07 Impact factor: 3.677

5. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.

Authors: Durga S Borkar; Mario E Lacouture; Surendra Basti
Journal: Support Care Cancer Date: 2012-11-15 Impact factor: 3.603

Trichomegaly following treatment with gefitinib (ZD1839).

1. Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review.

2. Gefitinib-induced hair alterations.

Review 3. Hair disorders in patients with cancer.

4. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer.

5. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.

Review 6. Ocular Toxicity of Targeted Anticancer Agents.

7. Epidermal growth factor receptor inhibitors related trichomegaly of Eyelashes.

8. Erlotinib induced trichomegaly of the eyelashes.

9. Eyelash Trichomegaly.

10. Dermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: 'PRIDE' Complex.